UTHR — United Therapeutics Balance Sheet
0.000.00%
- $13.09bn
- $10.12bn
- $2.88bn
- 100
- 69
- 64
- 92
Annual balance sheet for United Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,835 | 1,931 | 2,839 | 2,994 | 3,267 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 157 | 199 | 220 | 279 | 279 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,167 | 2,324 | 3,380 | 3,551 | 3,874 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 732 | 781 | 862 | 1,045 | 1,222 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 4,615 | 5,169 | 6,045 | 7,167 | 7,364 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 323 | 305 | 343 | 804 | 738 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,220 | 1,210 | 1,248 | 1,182 | 920 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 3,395 | 3,959 | 4,797 | 5,985 | 6,444 |
Total Liabilities & Shareholders' Equity | 4,615 | 5,169 | 6,045 | 7,167 | 7,364 |
Total Common Shares Outstanding |